Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14968886 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL14968885 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL2915027 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL5688911 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL21638328 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL10538624 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL20866020 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL20866021 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL29403468 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL5688908 | 0.98 | TSHR (0.61) | ALDH1A1TSHRFASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928461-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | claimed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-118324762-A | Compounds and compositions for treating CNS disorders | 布鲁奥科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4084797-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | Blue Oak Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ALDH1A1 612/4885TSHR 3315/4885FASN 902/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885TSHR 2165/4885FASN 1405/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885TSHR 2165/4885FASN 1405/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | ALDH1A1 612/4885TSHR 3315/4885FASN 902/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ALDH1A1 1221/4885TSHR 4163/4885FASN 4328/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885TSHR 2165/4885FASN 1405/4885 |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ALDH1A1 1058/4885TSHR 3711/4885FASN 1216/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | ALDH1A1 612/4885TSHR 3315/4885FASN 902/4885 |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | ALDH1A1 612/4885TSHR 3315/4885FASN 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.